Peter de Keizer (Associate Professor, University Medical Center Utrecht, Netherlands) and founder and managing director of Cleara Biotech B.V. discusses his drive to understand how cells that stop dividing and enter a “holding pattern,” known to cell biologists as senescence, drive disease and aging. We talk about how the peptides he has developed, called FOXO4 peptides, will enter clinical trials next year in patients with liver metastases. They work by selectively killing senescent cells, which in turn might unlock localized tissue regeneration programs. This is really cool stuff, and I bet most of you have never heard of this sort of approach!
Also, our recurring guest, a board-certified radiologist and medical malpractice lawyer who goes by the pseudonym Dr. MedLaw, answers all our questions about liability associated with referrals, something we all do and probably haven’t considered to the depth she covers.
Let us know what you thought of this week’s episode on Twitter: @physicianswkly
Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com!
Thanks for listening!